EdgarLookup

ENANTA PHARMACEUTICALS INC — 8-K Filings

107 8-K filings on record

This page lists all 8-K filings submitted to the SEC by ENANTA PHARMACEUTICALS INC (ENTA), sorted by most recent first. Each row links to the full filing on EdgarLookup. ENANTA PHARMACEUTICALS INC has filed 107 8-K documents with the SEC since 2002. To view all SEC filings by ENANTA PHARMACEUTICALS INC, see the full filings list.

Overview All Filings Financials Insiders
All 10-K 10-K/A 10-Q 144 3 3/A 4 4/A 424B4 424B5 8-A12B 8-K 8-K/A ARS CERTNAS CORRESP CT ORDER DEF 14A DEFA14A DEFR14A EFFECT NT 10-Q POSASR REGDEX S-1 S-1/A S-3 S-3ASR S-8 SC 13D SC 13D/A SC 13G SC 13G/A SCHEDULE 13D/A SCHEDULE 13G SCHEDULE 13G/A UPLOAD
Form Description Accession Number Filed Period
8-K 8-K 0001193125-26-125113 Mar 26, 2026 Mar 20, 2026
8-K 8-K 0001193125-26-104109 Mar 12, 2026 Mar 11, 2026
8-K 8-K 0001193125-26-042812 Feb 9, 2026
8-K 8-K 0001193125-25-284633 Nov 17, 2025
8-K 8-K 0001193125-25-226828 Oct 1, 2025 Sep 30, 2025
8-K 8-K 0001193125-25-221527 Sep 29, 2025
8-K 8-K 0001193125-25-221791 Sep 29, 2025
8-K 8-K 0001193125-25-189691 Aug 27, 2025 Aug 26, 2025
8-K 8-K 0001193125-25-183719 Aug 20, 2025
8-K 8-K 0001193125-25-177941 Aug 11, 2025
8-K 8-K 0000950170-25-069155 May 12, 2025
8-K 8-K 0000950170-25-040230 Mar 17, 2025 Mar 13, 2025
8-K 8-K 0000950170-25-017035 Feb 10, 2025
8-K 8-K 0001193125-24-272936 Dec 9, 2024
8-K 8-K 0000950170-24-130553 Nov 25, 2024
8-K 8-K 0000950170-24-090722 Aug 5, 2024
8-K 8-K 0000950170-24-053532 May 6, 2024
8-K 8-K 0000950170-24-029889 Mar 12, 2024 Mar 6, 2024
8-K 8-K 0000950170-24-012186 Feb 7, 2024
8-K 8-K 0001193125-23-303014 Dec 26, 2023 Dec 19, 2023
8-K 8-K 0000950170-23-065087 Nov 20, 2023
8-K 8-K 0000950170-23-039051 Aug 7, 2023
8-K 8-K 0000950170-23-026739 Jun 7, 2023
8-K 8-K 0000950170-23-018788 May 8, 2023
8-K 8-K 0001193125-23-122434 Apr 27, 2023 Apr 25, 2023
8-K 8-K 0000950170-23-007317 Mar 10, 2023
8-K 8-K 0000950170-23-006453 Mar 7, 2023 Mar 2, 2023
8-K 8-K 0000950170-23-001981 Feb 7, 2023
8-K 8-K 0000950170-22-025532 Nov 21, 2022
8-K 8-K 0001193125-22-231310 Aug 26, 2022
8-K 8-K 0000950170-22-015505 Aug 8, 2022
8-K 8-K 0001193125-22-178106 Jun 22, 2022 Jun 21, 2022
8-K 8-K 0001193125-22-153071 May 17, 2022 May 12, 2022
8-K 8-K 0000950170-22-008469 May 9, 2022
8-K 8-K 0000950170-22-003221 Mar 9, 2022 Mar 3, 2022
8-K 8-K 0000950170-22-003118 Mar 8, 2022 Mar 3, 2022
8-K 8-K 0000950170-22-000875 Feb 8, 2022
8-K 8-K 0000950170-21-004845 Nov 22, 2021
8-K 8-K HATA DIRECTOR 0001564590-21-045408 Aug 23, 2021 Aug 19, 2021
8-K 8-K 0001564590-21-041571 Aug 5, 2021
8-K 8-K NATHALIE ADDA RETIREMENT 0001564590-21-036895 Jul 16, 2021 Jul 14, 2021
8-K 8-K Q2 2021 EARNINGS RELEASE 0001564590-21-024938 May 6, 2021
8-K 8-K PROXY VOTE 0001564590-21-011253 Mar 5, 2021 Mar 2, 2021
8-K 8-K 0001564590-21-004686 Feb 8, 2021
8-K 8-K ABBVIE 8.01 OTHER EVENTS 0001564590-21-004518 Feb 5, 2021
8-K 8-K 0001564590-20-056183 Dec 4, 2020 Dec 1, 2020
8-K 8-K Q4 2020 0001564590-20-054888 Nov 23, 2020
8-K 8-K 0001564590-20-036125 Aug 4, 2020
8-K 8-K NEW DIRECTOR - MARK FOLETTA 0001564590-20-031261 Jun 30, 2020 Jun 29, 2020
8-K 8-K Q2 2020 EARNINGS RELEASE 0001564590-20-021925 May 6, 2020